“…Several studies have assessed the implications of using AXB for lung SBRT treatment planning. 7 , 8 , 9 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 In most cases, the effect in dose-volume parameters is below 2% except for the target coverage, which is considerably lower, and the Dw maximum dose in bony structures, which is significantly higher, in AXB-recalculated plans, as happens when MC is adopted. 31 Certain studies used an older version of AXB (v10), 7 , 8 , 9 , 21 , 25 , 26 , 30 which differs from more recent versions in many respects, most importantly with regard to computed tomography (CT)-to-material conversions.…”